Novartis sells portions of Sandoz US portfolio to Aurobindo

06-09-2018

Novartis sells portions of Sandoz US portfolio to Aurobindo

Obencem / iStockphoto.com

Novartis has revealed plans to sell the dermatology business and generic US oral solids portfolios of its subsidiary Sandoz US to India-based Aurobindo for $900 million.


Novartis, Sandoz, Aurobindo, mergers and acquisitions, M&A, generics, dermatology, oral solids

LSIPR